Beta-cell preservation in type 1 diabetes

Type 1 diabetes (T1D) is a progressive autoimmune disease marked by the gradual loss of pancreatic beta cells.[1] Many individuals retain **residual beta-cell function** at and after diagnosis.[2] Preserving this function is clinically important and should be considered when counseling patients who test positive for T1D-associated autoantibodies or are newly diagnosed.

Family physicians play a critical role in the **early identification, patient education** and **timely referral**, particularly as T1D is increasingly recognized as a staged disease with a prolonged presymptomatic phase.[3]

Beta-cell preservation is important because it[4]:

- Supports more stable glycemic control.
- Reduces the risk of severe hypoglycemia and diabetic ketoacidosis.
- Lowers insulin requirements and treatment burden.
- Delays or reduces the risk of long-term complications.
- Improves the quality of life and the transition to insulin dependence.

T1D as a staged-disease continuum[3]

Stage	Clinical features	Beta-cell status	Primary care role
Stage 1	Multiple T1D autoantibodies, normoglycemia	Largely preserved	Identify risk, educate families, and monitor progression and progress
Stage 2	Autoantibodies plus dysglycemia	Declining but present	Close follow-up care and coordinate specialty care
Stage 3	Symptomatic hyperglycemia (clinical T1D)	Reduced but often measurable	Support early management of care and reduce acute risk

Clinical impact of preserved beta-cell function

Preserved beta-cell function in T1D is associated with improved glycemic stability, a lower risk of severe hypoglycemia and diabetic ketoacidosis, and reduced insulin requirements.[4] Over time, residual betacell activity is also linked to a lower risk of diabetes-related complications and a reduced overall treatment burden, supporting better quality of life.

Early detection of T1D by family physicians is important to achieve the following progression[4,5]:

Autoantibodies detected
↓
Residual beta-cell function present
↓
Opportunity for monitoring and education
↓
Reduced acute complications at diagnosis
↓
Improved long-term outcomes

Key points for beta-cell preservation include[4,5]:

- T1D progression is gradual, not abrupt.
- Residual beta-cell function is common and clinically important.
- Preservation is linked to better metabolic and safety outcomes.
- Family physicians are essential in early recognition and education.

References

1. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care.* 2015;38(10):19641974.
2. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of Cpeptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. *Diabetes.* 2014;63(2):739748.
3. ElSayed NA, Aleppo G, Aroda VR, et al. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2023. *Diabetes Care.* 2022;46(Suppl 1):S19S40.
4. Lam A, Dayan C, Herold KC. A little help from residual β cells has long-lasting clinical benefits. *J Clin Invest.* 2021;131(3):e143683.
5. Lan Y, Kovinthapillai, Kedzia A, et al. Enhancing primary care recognition of type 1 diabetes in children: diagnostic challenges and strategies to prevent diabetic ketoacidosis. *J Clin Med.* 2026;15(2):533.

This content was independently developed by the American Academy of Family Physicians with support provided by Sanofi. | HOP260416117